Xenon Pharmaceuticals Inc
XP0
Company Profile
Business description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Contact
200-3650 Gilmore Way
BurnabyBCV5G 4W8
CANT: +1 604 484-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
370
Stocks News & Analysis
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.30 | 34.80 | -0.40% |
| CAC 40 | 7,807.87 | 162.01 | -2.03% |
| DAX 40 | 22,839.56 | 662.69 | -2.82% |
| Dow JONES (US) | 46,021.43 | 203.72 | -0.44% |
| FTSE 100 | 10,079.73 | 16.23 | 0.16% |
| HKSE | 25,274.40 | 226.18 | -0.89% |
| NASDAQ | 22,090.69 | 61.73 | -0.28% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 12,989.99 | 61.62 | -0.47% |
| S&P 500 | 6,606.49 | 18.21 | -0.27% |
| S&P/ASX 200 | 8,428.40 | 43.90 | -0.52% |
| SSE Composite Index | 3,957.05 | 49.50 | -1.24% |